Q1 FY2024 · ended Mar 31, 2024 · Revenue $1.06M, +55.9% YoY · Filed May 6, 2024
Panacea Life Sciences Holdings, Inc. (PLSH) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q1 of fiscal 2024, the quarter ended Mar 31, 2024, it reported revenue of $1.1 million and a net loss of $1.4 million. Free cash flow was -$362,090. As of Mar 31, 2024 it held $117,147 in cash and investments and $3.8 million in total debt.
Revenue
$1.06M
+55.9% vs year-ago quarter
Net income
$-1.45M
+19.3% vs year-ago quarter
Operating cash flow
$-357,090
-13.8% vs year-ago quarter
Free cash flow
$-362,090
-10.0% vs year-ago quarter
EPS
$-0.09
+32.1% vs prior quarter
Dividend per share
None
Shares outstanding
17.65M
+13.8% vs year-ago quarter
Net cash
$-3.68M
Q1 FY2024
Operating margin
-192.2%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- PLSH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Greenwood Village, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1552189
- Former names
- Exactus, Inc. (until Oct 26, 2021); Spiral Energy Tech., Inc. (until Mar 4, 2016); Solid Solar Energy, Inc. (until Aug 7, 2013)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2024 Mar 31, 2024 |
Q4 FY2023 Dec 31, 2023 |
Q3 FY2023 Sep 30, 2023 |
Q2 FY2023 Jun 30, 2023 |
Q1 FY2023 Mar 31, 2023 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $960,496 | $347,851 | $399,128 | $677,481 |
| Operating income | -$1.1M | -$1.8M | -$1.4M | -$1.1M | -$1.3M |
| Net income | -$1.4M | -$2.2M | -$2.2M | -$1.9M | -$1.8M |
| Diluted EPS | -$0.09 | -$0.13 | -$0.13 | -$0.11 | — |
| Operating cash flow | -$357,090 | $1,573 | -$728,869 | -$483,316 | -$313,851 |
| Free cash flow | -$362,090 | -$78,066 | — | -$492,666 | -$329,071 |
| Total assets | $17.4M | $18.0M | $18.7M | $17.9M | $18.6M |
| Total liabilities | $27.0M | $26.3M | $24.8M | $23.4M | $22.4M |
| Stockholders' equity | -$9.6M | -$8.3M | -$6.1M | -$5.6M | -$3.8M |
| Cash and investments | $117,147 | $115,855 | $79,915 | $468,578 | $998,339 |
| Total debt | $3.8M | $4.0M | $3.1M | $3.2M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
May 16, 2024 | May 13, 2024 |
| 8-K |
Current report
Auditor change
|
May 7, 2024 | May 3, 2024 |
| 10-Q | Quarterly report | May 6, 2024 | Mar 31, 2024 |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Material agreement, New debt
|
Mar 7, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Material agreement
|
Feb 5, 2024 | Jan 29, 2024 |
All 316 Panacea Life Sciences Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.